• Lei Chen, Annie Guérin, Jipan Xie, Eric Q Wu, Andrew P Yu, Solveig G Ericson, and Elias Jabbour.
• Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA. lei.chen@novartis.com
• Curr Med Res Opin. 2012 Nov 1; 28 (11): 183118391831-9.

ObjectivesMonitoring treatment response is an integral part of chronic myeloid leukemia (CML) treatment. The guidelines recommend regular monitoring using standard methods (e.g., real-time quantitative polymerase chain reaction based on the international scale for molecular response) and treatment adjustment when failure is detected among patients treated with imatinib. The objective of this study was to assess the real-world monitoring and therapy adjustment in this patient population in the US.MethodsTwenty-nine physicians from community practices across the US participated in an online chart review. Adult patients with chronic phase CML who initiated imatinib as first-line therapy during 2006-2010 were selected. Information was collected up to 36 months after imatinib initiation, including response monitoring, response status, and therapy adjustment upon treatment failure.ResultsThe study included 297 eligible patients. By 18 months, 47% of patients had received cytogenetic response assessment continuously as recommended by the guidelines. The corresponding proportion was 39% for continuous molecular response assessment. Among patients who experienced treatment failure by 18 months, only 14%-38% of patients switched to a second-generation tyrosine kinase inhibitor as recommended by the National Comprehensive Cancer Network and the European Leukemia Net guidelines.LimitationsMajor limitations included limited generalizability and the inability to accurately assess molecular response due to the variations in testing methods during the study period.ConclusionsBased on the guidelines, the rates of treatment monitoring and switching upon failure were low, demonstrating the need for improvement in CML care in community settings in the US.

23 keywords...

hide…